Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.82 CAD
Change Today 0.00 / 0.00%
Volume 0.0
RBM On Other Exchanges
Symbol
Exchange
Toronto
OTC BB
Stuttgart
Frankfurt
As of 4:10 PM 03/26/15 All times are local (Market data is delayed by at least 15 minutes).

response biomedical corp (RBM) Snapshot

Open
C$0.82
Previous Close
C$0.82
Day High
C$0.82
Day Low
C$0.82
52 Week High
08/13/14 - C$1.89
52 Week Low
12/31/14 - C$0.66
Market Cap
8.0M
Average Volume 10 Days
1.3K
EPS TTM
C$-1.16
Shares Outstanding
9.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RESPONSE BIOMEDICAL CORP (RBM)

Related News

No related news articles were found.

response biomedical corp (RBM) Related Businessweek News

No Related Businessweek News Found

response biomedical corp (RBM) Details

Response Biomedical Corp. is engaged in the research, development, commercialization, and distribution of diagnostic technologies for the medical central-lab testing, point of care (POC) testing, and on-site environmental testing markets. The POC and on-site diagnostic tests are non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges, and/or dipsticks. It provides RAMP system, which is a portable fluorescence immunoassay-based diagnostic technology that combines the performance of a clinical lab with the convenience of a dipstick test. The company’s RAMP tests are used in the early detection of heart attack, congestive heart failure, influenza A+B, the respiratory syncytial virus, and environmental detection of West Nile Virus; and biodefense applications, including the rapid on-site detection of anthrax, smallpox, ricin, and botulinum toxin. Response Biomedical Corp. sells its products through distributors primarily in China, the United States, Asia, Europe, Canada, and internationally. The company was founded in 1980 and is headquartered in Vancouver, Canada.

68 Employees
Last Reported Date: 03/19/15
Founded in 1980

response biomedical corp (RBM) Top Compensated Officers

Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$241.5K
Compensation as of Fiscal Year 2013.

response biomedical corp (RBM) Key Developments

Response Biomedical Corp. Auditor Raises 'Going Concern' Doubt

Response Biomedical Corp. filed its 10-K on Mar 19, 2015 for the period ending Dec 31, 2014. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Response Biomedical Corp. Announces Consolidated Unaudited Earnings Results for Fourth Quarter and Full Year Ended December 31, 2014

Response Biomedical Corp. announced consolidated unaudited earnings results for fourth quarter and full year ended December 31, 2014. For the quarter, the company reported total revenue of CAD 3,179,000, net income and comprehensive income of CAD 77,000 or CAD 0.03 per diluted share, adjusted LBITDA of CAD 1,072,000, adjusted net loss of CAD 1,575,000 compared to the total revenue of CAD 3,134,000, net income and comprehensive income of CAD 3,172,000 or loss of CAD 0.1 per diluted share, adjusted LBITDA of CAD 235,000, adjusted net loss of CAD 769,000 for the same quarter a year ago. The decrease in GAAP net income was primarily due to a CAD 2.3 million decrease in the unrealized gain on revaluation of the warrant liability offset by the decrease in gross margin and increase in operating expenses. For the year, the company reported total revenue of CAD 11,014,000, net loss and comprehensive loss of CAD 2,090,000 or CAD 0.89 per diluted share, adjusted LBITDA of CAD 3,960,000, adjusted net loss of CAD 6,092,000 compared to the total revenue of CAD 11,531,000, net loss and comprehensive loss of CAD 5,998,000 or CAD 0.89 per diluted share, adjusted LBITDA of CAD 1,681,000, adjusted net loss of CAD 3,884,000 for the previous year. The decrease in the loss was primarily due to a CAD 6.1 million increase in the unrealized gain on revaluation of the warrant liability offset by the decrease in product sales, gross margin on product sales, and increase in operating expenses.

Response Biomedical Corp. to Report Q4, 2014 Results on Mar 16, 2015

Response Biomedical Corp. announced that they will report Q4, 2014 results at 2:00 PM, Pacific Standard Time on Mar 16, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RBM:CN C$0.82 CAD 0.00

RBM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $144.59 USD +1.38
Cepheid $54.14 USD +0.93
Quidel Corp $27.15 USD +0.63
Siemens AG €101.30 EUR +1.24
View Industry Companies
 

Industry Analysis

RBM

Industry Average

Valuation RBM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESPONSE BIOMEDICAL CORP, please visit www.responsebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.